What is Better for Weight Loss: Semaglutide or Tirzepatide?

Last reviewed: June 5, 2026

Last updated: June 5, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Both semaglutide and tirzepatide have shown significant weight reduction in clinical trials, but they work through distinct biological mechanisms. Understanding how each medication functions can help you and your provider determine which approach aligns with your metabolic profile and weight loss objectives.

How Semaglutide Works for Weight Loss

Semaglutide is a GLP-1 receptor agonist, meaning it activates a single pathway in your body that regulates appetite and blood sugar. When semaglutide binds to GLP-1 receptors in the brain and gut, it slows stomach emptying, increases feelings of fullness, and reduces hunger signals. This mechanism has been studied extensively, with trials showing average weight reductions of 10–15% of body weight over 68 weeks in patients with obesity.

The medication works best when combined with consistent lifestyle changes including dietary modifications and increased physical activity. Many patients report that semaglutide makes adherence to a calorie-reduced diet easier because appetite suppression occurs naturally rather than through willpower alone. PlexusDx offers compounded semaglutide in both injection and oral formulations, allowing flexibility based on your preference and tolerance.

The Dual-Receptor Advantage of Tirzepatide

Tirzepatide activates two receptor pathways simultaneously: GLP-1 and GIP (glucose-dependent insulinotropic polypeptide). This dual-receptor approach creates a more comprehensive metabolic effect than single-pathway GLP-1 agonists. Clinical trials have demonstrated that tirzepatide produces greater average weight loss—up to 20–22% of body weight—compared to semaglutide alone, with the advantage appearing more pronounced at higher dose levels.

The GIP receptor activation in tirzepatide enhances insulin secretion when glucose is high, improves energy expenditure, and may provide additional appetite suppression through a different neural pathway. This combination allows tirzepatide to address multiple hunger and satiety mechanisms simultaneously. PlexusDx delivers compounded tirzepatide injections at $289/mo month-to-month, or from $249/mo on the 6-month plan, with oral formulations also available for patients who prefer non-injectable administration.

Key Differences in Weight Loss Efficacy

Head-to-head comparison trials show that tirzepatide consistently achieves numerically greater weight loss than semaglutide at equivalent time points. In the SURPASS-2 trial, patients on tirzepatide lost approximately 20.9% of body weight versus 16.0% on semaglutide (both at comparable doses) over 40 weeks. However, individual response varies significantly based on genetics, lifestyle, baseline metabolic factors, and adherence.

The PlexusDx Precision Peptide Genetic Test analyzes GIPR, FTO, and MC4R — variants that relate to GLP-1 and related signaling pathways. It does not predict your response to tirzepatide or determine your dose; it offers pathway-level context for a conversation with your provider. Genetics is a guide, not a guarantee.

Cost, Convenience, and Personalized Selection

PlexusDx compounded semaglutide injections are $189/mo month-to-month, or from $149/mo on the 6-month plan, while tirzepatide injections begin at $289/mo (or $249/mo on the 6-month plan). Your dose may need to go up as you progress through treatment—your price won't. Both medications are available without insurance requirements, are HSA/FSA eligible, and ship to all 50 states from licensed 503A compounding pharmacies meeting rigorous pharmaceutical standards.

Choosing between semaglutide and tirzepatide involves weighing cost, expected efficacy, injection frequency preferences, and your individual health profile. PlexusDx providers can incorporate genetic insights through the Precision Peptide Genetic Test ($298) to identify peptide-pathway predispositions that may inform whether semaglutide's single-receptor approach or tirzepatide's dual mechanism better matches your metabolic genetics. PlexusDx also offers GLP-Squared, a dual-compound injection combining both medications for advanced metabolic control at $289/mo month-to-month, or from $249/mo on the 3-month plan.

Side Effects and Tolerability Considerations

Both semaglutide and tirzepatide commonly cause gastrointestinal side effects including nausea, vomiting, diarrhea, and constipation, particularly during dose escalation. These effects are typically mild to moderate and tend to diminish over 2–4 weeks as your body adjusts. Some patients tolerate one medication better than the other due to individual gut sensitivity and genetic factors affecting peptide receptor expression.

Serious adverse events including pancreatitis, gallbladder disease, and severe dehydration are rare but require medical monitoring. PlexusDx patients receive ongoing provider support to manage side effects, adjust dosing protocols, and determine whether a medication switch might improve tolerability. The microdose GLP-1 protocol ($129/month) offers a gentler entry option for patients concerned about initial side effects or those seeking lower-intensity metabolic support.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection is $289/mo month-to-month, or from $249/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $298 to personalize your protocol from day one.

Frequently Asked Questions

Which medication causes more weight loss—semaglutide or tirzepatide?

Clinical trials show tirzepatide produces greater average weight loss (20–22% of body weight) compared to semaglutide (10–15%), primarily due to its dual GLP-1 and GIP receptor activation. Individual results vary significantly based on genetics, lifestyle adherence, and metabolic factors. PlexusDx providers can discuss whether tirzepatide's additional efficacy justifies its $289/month starting cost versus semaglutide's $189/month entry price for your specific goals.

Can I switch from semaglutide to tirzepatide if I'm not seeing results?

Yes, switching between medications is a common clinical strategy if one isn't meeting your weight loss targets or if tolerability becomes an issue. Your PlexusDx provider can design a transition protocol to safely switch therapies while minimizing side effects. Some patients benefit from tirzepatide's dual-receptor mechanism after plateauing on semaglutide alone.

Is tirzepatide more expensive than semaglutide with PlexusDx?

Tirzepatide injections are $289/mo month-to-month, or from $249/mo on the 6-month plan compared to semaglutide injections at $189/mo month-to-month, or from $149/mo on the 6-month plan—a $100 monthly difference. Both medications maintain flat pricing across dose increases, so your price won't rise as your dose adjusts. Oral formulations of both are also available, with tirzepatide oral at $349/mo month-to-month, or from $279/mo on the 6-month plan.

How does the Precision Peptide Genetic Test relate to your GLP-1 pathway?

PlexusDx's Precision Peptide Genetic Test identifies key variants in GIPR and FTO, and MC4R pathways that influence your peptide responsiveness across 14 metabolic mechanisms. Certain genetic predispositions may suggest stronger benefit from tirzepatide's GIP activation, while others may indicate excellent response to semaglutide's single-pathway approach. This $99 add-on test, supports truly personalized medication selection.

Are compounded semaglutide and tirzepatide from PlexusDx as safe as brand-name versions?

PlexusDx medications are manufactured by licensed 503A compounding pharmacies operating under strict pharmaceutical quality standards. While compounded medications are not FDA-approved like brand versions, 503A compounds are legally required to meet identical purity, potency, and sterility standards. Your PlexusDx provider monitors safety and efficacy throughout treatment with ongoing clinical support.

Can I use HSA or FSA funds to pay for PlexusDx medications?

Yes, both semaglutide and tirzepatide from PlexusDx are HSA and FSA eligible, reducing your out-of-pocket cost if you have these tax-advantaged accounts. PlexusDx serves all 50 states without requiring insurance, membership fees, or prior authorization, making precision GLP-1 therapy accessible regardless of your coverage status.

Related Reading

• Tirzepatide Vs Semaglutide For Weight Loss
• Semaglutide For Weight Loss 2
• Tirzepatide For Weight Loss 2
• Semaglutide Tablets For Weight Loss

Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.